Skip to content
HowShorted

INmune Bio Inc. short interest in 2023

In 2023, INmune Bio Inc.'s disclosed short interest ran from 5.50% of shares outstanding on 13 Jan 2023 to 6.11% on 29 Dec 2023, a change of +0.61 percentage points. The year's high was 7.13% on 13 Oct 2023 and its low 5.50% on 13 Jan 2023, averaging 6.19% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 46.51 days on 31 Aug 2023. Full history: INmune Bio Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for INmune Bio Inc. in 2023

2023 in figures

Start of year
5.50% (13 Jan 2023)
End of year
6.11% (29 Dec 2023)
Change
+0.61 pp
High
7.13% (13 Oct 2023)
Low
5.50% (13 Jan 2023)
Average
6.19%
Highest days to cover
46.51 (31 Aug 2023)
SEC filings marked
8

Every report in 2023

INmune Bio Inc. short interest in 2023
SettlementShort interestDays to coverFilings since previous
13 Jan 20235.50%17.54
31 Jan 20236.02%13.53
15 Feb 20236.02%22.96
28 Feb 20235.99%29.69
15 Mar 20235.89%20.5010-K filed, results (8-K)
31 Mar 20235.90%14.77
14 Apr 20235.84%16.89
28 Apr 20235.75%35.12
15 May 20235.74%21.9510-Q filed, results (8-K)
31 May 20235.72%30.57
15 Jun 20235.83%16.84
30 Jun 20236.12%24.61
14 Jul 20236.15%9.58
31 Jul 20236.34%15.34
15 Aug 20236.34%30.7310-Q filed, results (8-K)
31 Aug 20236.33%46.51
15 Sep 20236.23%31.46
29 Sep 20237.04%19.38
13 Oct 20237.13%27.29
31 Oct 20236.78%37.25
15 Nov 20236.70%38.0010-Q filed, results (8-K)
30 Nov 20236.67%34.25
15 Dec 20236.34%12.01
29 Dec 20236.11%13.66

See also: INmune Bio Inc.'s full history · most shorted US stocks of 2023 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.